Tanabe Research Laboratories

uses cutting-edge research and development techniques to advance novel biological drugs for oncology and other diseases. Our pipeline, mainly focused on antibody-drug conjugates (ADCs), includes potential therapies that target specific molecules on cancer cells and modulate cancer cell function in ways that hold promise to improve human health.

In addition

to our internal work to identify unique targets associated with cancer cells, we have established collaborations with academic groups and other companies to use cutting-edge technologies, including mass spectroscopy-based proteomics approaches. We have successfully identified several unique candidates associated with refractory cancers as targets for ADC-based therapeutic approaches.

Through our collaboration

with MedImmune/AstraZeneca, we have employed highly potent specific pyrrolobenzodiazepine (PBD) molecules as cytotoxins for cancer therapy. Our technology platforms include conventional antibodies as well as engineered scaffolds, non-antibody binding proteins, bispecific molecules and others. Through our partners, we have used various innovative technologies for human antibody generation and selection.

In collaboration

with our partner Covagen, we have developed a bispecific molecule that binds IL6-R and IL-17A by using Covagen’s FynomAb® technology. This was developed for the treatment of various autoimmune and inflammatory diseases but is also being explored for its use in oncology.

A Career with Tanabe Research Laboratories

Interested in joining our team? We seek out scientists who work with honesty and integrity; who are willing to push the boundaries and explore new ideas; who take ownership and thrive on accountability; and who perform their work with a sense of urgency, but do so with an optimistic and solution-oriented attitude.